Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Developing transformative, best-in-class neuropsychiatric therapies
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
Develops therapeutics for pulmonary diseases, specifically COPD
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions